home / stock / gnmsf / gnmsf short
Short Information | Genmab A/S Dkk (OTCMKTS:GNMSF)
Twenty Trading Day Totals | |
---|---|
Total Shorted Volume | 3,803 |
Total Actual Volume | 12,079 |
Short Trends | |
---|---|
Cover Days | 15 |
Short Days | 3 |
No Change Days | 2 |
Averages | |
---|---|
Average Short Volume | 190 |
Average Short Percentage | 25.08% |
Is there a GNMSF Short Squeeze or Breakout about to happen?
See the GNMSF Short Analysis for free Sign up or Login
Powered by Squeeze Report
Date | Open | Close | High | Low | Total Volume | Short Volume | Short Percentage |
---|---|---|---|---|---|---|---|
07-02-2024 | $241.09 | $241.09 | $250.66 | $241.09 | 1,121 | 83 | 7.4% |
07-01-2024 | $251.138 | $254.76 | $254.76 | $244.19 | 1,227 | 936 | 76.28% |
06-28-2024 | $244.68 | $245.4875 | $255.55 | $244.68 | 651 | 169 | 25.96% |
06-27-2024 | $254.6 | $262.02 | $262.02 | $252.18 | 425 | 119 | 28% |
06-26-2024 | $251.09 | $260.96 | $260.96 | $251.09 | 282 | 34 | 12.06% |
06-25-2024 | $253.01 | $253.01 | $262.94 | $253.01 | 595 | 28 | 4.71% |
06-24-2024 | $261 | $256.42 | $266.76 | $256.42 | 1,437 | 601 | 41.82% |
06-21-2024 | $254.16 | $254.16 | $259.29 | $254.16 | 227 | 74 | 32.6% |
06-17-2024 | $254.2 | $264.1 | $264.1 | $254.2 | 480 | 73 | 15.21% |
06-14-2024 | $267.11 | $258.44 | $267.11 | $255.55 | 728 | 151 | 20.74% |
06-13-2024 | $267.49 | $267.49 | $267.49 | $259.96 | 682 | 30 | 4.4% |
06-11-2024 | $266.8 | $266.8 | $272.95 | $266.8 | 460 | 15 | 3.26% |
06-10-2024 | $282.45 | $270.92 | $282.45 | $270.92 | 1,224 | 948 | 77.45% |
06-07-2024 | $283.24 | $272.86 | $283.24 | $270 | 365 | 4 | 1.1% |
06-05-2024 | $284.48 | $284.872 | $290.218 | $284.48 | 265 | 19 | 7.17% |
06-04-2024 | $278.61 | $287.844 | $289.14 | $268.61 | 387 | 17 | 4.39% |
06-03-2024 | $289.01 | $288.24 | $289.01 | $270.36 | 403 | 260 | 64.52% |
05-31-2024 | $275.67 | $275.67 | $286.08 | $275.67 | 443 | 48 | 10.84% |
05-30-2024 | $285.23 | $284.276 | $285.23 | $265.61 | 423 | 81 | 19.15% |
05-29-2024 | $284.84 | $274.46 | $284.84 | $274.46 | 254 | 113 | 44.49% |
News, Short Squeeze, Breakout and More Instantly...
Company Announcement Positive CHMP opinion based on results from the Phase 1/2 EPCORE ® NHL-1 study FL is the second most common type of NHL and accounts for approximately 20-30 percent of all global cases If approved, epcoritamab (TEPKINLY ® ...
Company Announcement Genmab has completed acquisition of ProfoundBio for USD 1.8 billion in cash Acquisition gives Genmab worldwide rights to three candidates in clinical development, including rinatabart sesutecan (Rina-S), plus ProfoundBio’s novel antibody-drug conjugat...
May 2, 2024 Copenhagen, Denmark; Interim Report for the First Quarter Ended March 31, 2024 Highlights The U.S. Food and Drug Administration (U.S. FDA) granted Priority Review for the supplemental Biologics License Application (sBLA) for EPKINLY ® (epcorita...